ArticleWorld journal of stem cells2025
Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study.
Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions.World journal of stem cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety and efficacy of recombinant human thrombopoietin (rhTPO) administered after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children (0-9 years old) and adolescents (10-17 years old) with hematological disorders remain unclear.
aimTo evaluate the safety and efficacy of rhTPO administered before platelet (PLT) engraftment in pediatric patients with hematological disorders undergoing HSCT, and to investigate its effects on the incidence of graft-
methodsThis study enrolled 79 pediatric patients with hematological disorders who received rhTPO after allo-HSCT. The safety and tolerability of rhTPO were evaluated and compared in children (
resultsAll of the children and adolescents underwent hematopoietic reconstruction. The median time to PLT engraftment was 16 days for all patients, with 14 (range, 11-24) days in the 0- to 9-year-old group and 16 (range, 11-41) days in the 10- to 17-year-old group; the difference was statistically significant (
conclusionrhTPO was not associated with any significant safety issues and was well tolerated by pediatric and adolescent patients with hematologic diseases who underwent allo-HSCT. Our results suggested that rhTPO may benefit allo-HSCT in children and adolescents by improving PLT recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.